SanBio Books Foreign Exchange Losses and Financing Costs in FY2026 Results

SanBio Co ( (JP:4592) ) has issued an update.

SanBio Co., Ltd. reported several non-operating expenses for the fiscal year ending January 31, 2026, including ¥29 million in bond interest tied to convertible bonds with stock acquisition rights and a ¥45 million charge in financing expenses mainly from committed credit line fees. The company also incurred ¥94 million in stock issuance costs related to new share and bond offerings, and booked a ¥326 million foreign exchange loss on foreign currency loans to a subsidiary, partly offset by a ¥321 million foreign currency translation adjustment and recognition of negative ¥450 million in deferred income taxes linked to those foreign currency-denominated assets.

These items reflect the financial impact of SanBio’s ongoing funding and capital markets activities, as well as currency volatility affecting its cross-border intra-group financing. While the company has detailed that the net effect of these non-operating expenses and deferred tax adjustments will be reflected in its full-year earnings, investors will need to examine the latest consolidated financial results to assess how these charges influence profitability, capital structure, and future financing flexibility.

The most recent analyst rating on (JP:4592) stock is a Hold with a Yen2054.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.

More about SanBio Co

SanBio Co., Ltd. is a Japan-based biopharmaceutical company listed on the TSE Growth Market under code 4592. The company focuses on developing and commercializing regenerative medicine and cell therapy products, targeting neurological and other unmet medical needs in domestic and overseas markets.

Average Trading Volume: 1,356,507

Technical Sentiment Signal: Buy

Current Market Cap: Yen157.6B

See more insights into 4592 stock on TipRanks’ Stock Analysis page.